Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease. The company is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.
Location: Italy, Piedmont, Turin
Employees: 1-10
Total raised: $28.67M
Founded date: 2021
Funding Rounds 3
| Date | Series | Amount | Investors |
| 05.01.2024 | Series A | $10.95M | - |
| 22.02.2023 | Seed | $10.63M | Italian An... |
| 04.08.2021 | Seed | $7.1M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 05.01.2024 | Resalis Therapeutics Raises €10M in Series A Funding | Resalis Therapeutics, a Torino, Italy-based ncRNAs and RNA-targeted therapeutics company, raised €10... | finsmes.co... |
| 04.01.2024 | Torino-based Resalis raises €10 million Series A to provide ... | - | eu-startup... |
| 22.02.2023 | Resalis Therapeutics Raises €10M in Seed Financing | Resalis Therapeutics, a Torino, Italy-based company focused on finding treatments for metabolic dise... | finsmes.co... |
| - | Resalis Therapeutics | “Resalis Therapeutics – Tackling metabolic disorders with non-coding RNAs” | fastfounde... |